All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Nektar Therapeutics Inc. said it will cease all spending and partnership talks for Exubera after a new analysis of clinical trial data revealed an increased risk of lung cancer. (BioWorld Today)
